221 related articles for article (PubMed ID: 10100715)
21. [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients].
Nathrath M; Kremer M; Letzel H; Remberger K; Höfler H; Ulle T
Klin Padiatr; 2002; 214(4):230-5. PubMed ID: 12165907
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.
James R; May C; Diers M; Wagner J; McIvor R
Bone Marrow Transplant; 1999 Oct; 24(8):815-21. PubMed ID: 10516690
[TBL] [Abstract][Full Text] [Related]
23. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
Wolf J; Stranzl T; Filipits M; Pohl G; Pirker R; Leeb B; Smolen JS
Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
[TBL] [Abstract][Full Text] [Related]
24. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
Kastrup IB; Worm J; Ralfkiaer E; Hokland P; Guldberg P; Grønbaek K
Eur J Haematol; 2008 Jan; 80(1):61-6. PubMed ID: 18028428
[TBL] [Abstract][Full Text] [Related]
25. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
27. [Methotrexate and its drug resistance].
Nagura E
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2882-7. PubMed ID: 3178237
[TBL] [Abstract][Full Text] [Related]
28. DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo.
Matheson EC; Hogarth LA; Case MC; Irving JA; Hall AG
Carcinogenesis; 2007 Jun; 28(6):1341-6. PubMed ID: 17148505
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
Scionti I; Michelacci F; Pasello M; Hattinger CM; Alberghini M; Manara MC; Bacci G; Ferrari S; Scotlandi K; Picci P; Serra M
Ann Oncol; 2008 Aug; 19(8):1500-1508. PubMed ID: 18385200
[TBL] [Abstract][Full Text] [Related]
30. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
Zhao R; Chattopadhyay S; Hanscom M; Goldman ID
Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659
[TBL] [Abstract][Full Text] [Related]
31. Expression of the multidrug resistance gene in osteosarcoma: a pilot study.
Wunder JS; Bell RS; Wold L; Andrulis IL
J Orthop Res; 1993 May; 11(3):396-403. PubMed ID: 8100852
[TBL] [Abstract][Full Text] [Related]
32. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
James RI; May C; Vagt MD; Studebaker R; McIvor RS
Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
[TBL] [Abstract][Full Text] [Related]
33. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance.
Braun SE; McIvor RS; Davidson AS; Hanna M; Traycoff CM; Berebetsky DA; Gonin R; Broxmeyer HE; Cornetta K
Cancer Gene Ther; 1997; 4(1):26-32. PubMed ID: 9012448
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
35. Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene.
Mineishi S; Nakahara S; Takebe N; Zhao SC; Banerjee D; Bertino JR
Cancer Gene Ther; 1998; 5(3):144-9. PubMed ID: 9622097
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
38. Regulation of dihydrofolate reductase gene transcription in methotrexate-resistant mouse fibroblasts.
Wu JS; Johnson LF
J Cell Physiol; 1982 Feb; 110(2):183-9. PubMed ID: 6279683
[TBL] [Abstract][Full Text] [Related]
39. Expression of major vault protein gene in osteosarcoma patients.
Dalla-Torre CA; de Toledo SR; Yoshimoto M; Petrilli AS; Andrade JA; Chilton-MacNeill S; Squire JA; Zielenska M
J Orthop Res; 2007 Jul; 25(7):958-63. PubMed ID: 17415755
[TBL] [Abstract][Full Text] [Related]
40. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors.
Takebe N; Nakahara S; Zhao SC; Adhikari D; Ural AU; Iwamoto M; Banerjee D; Bertino JR
Cancer Gene Ther; 2000 Jun; 7(6):910-9. PubMed ID: 10880023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
